Skip to main content
PMC home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1993 Jun;46(6):507–512. doi: 10.1136/jcp.46.6.507

Immunohistochemical analysis of p53 expression in anal squamous neoplasia.

O A Ogunbiyi 1, J H Scholefield 1, J H Smith 1, S V Polacarz 1, K Rogers 1, F Sharp 1
PMCID: PMC501283  PMID: 8392521

Abstract

AIMS--To determine the pattern of expression of the p53 tumour suppressor gene product in anal squamous neoplasia, and to determine if this could be used as a marker of disease progression. The association between p53 expression and human papillomavirus (HPV) 16 DNA status of the anal lesions was also investigated. METHODS--The presence and localisation of the p53 protein in formalin fixed, paraffin wax embedded specimens of anal squamous epithelium (normal and neoplastic) was examined using immunohistochemical staining with a panel of two monoclonal antibodies (DO-1, DO-7) and one polyclonal antibody (CM-1). Thirty nine normal anal epithelia, 14 anal intraepithelial neoplasia (AIN) grade 1, seven AIN 2, and 20 AIN 3 specimens were obtained from patients without demonstrable invasive disease; twelve AIN 3 specimens adjacent to invasive disease and 34 anal squamous cancers were also examined. Genomic DNA from all 126 specimens was extracted and analysed for HPV 16 DNA using the polymerase chain reaction (PCR). RESULTS--Nuclear p53 was strongly expressed in 67% (23/34) of invasive anal squamous tumours, 75% (9/12) of AIN 3 specimens adjacent to invasive disease, and in 60% (12/20) of AIN 3 specimens obtained from patients without demonstrable invasive disease. Two of the patients in the latter group with positively staining specimens subsequently developed invasive tumours which had staining characteristics similar to those of the AIN 3 specimens. p53 protein was expressed in very low concentrations in low grade AIN and not at all in normal anal squamous epithelium. In those specimens which stained positively for p53, HPV 16 DNA sequences were detected in 69.5% (16/23) of invasive disease, 77.7% (7/9) of AIN 3 adjacent to invasive disease, 75% (9/12) of AIN 3 obtained from patients without demonstrable invasive disease, 33.3% (2/6) of AIN 2, and in 40% (2/5) of AIN 1. There was no significant correlation between p53 immunostaining and HPV 16 DNA status (p < 0.05). CONCLUSIONS--Aberrant expression of the p53 gene product is probably involved in the pathogenesis of anal squamous neoplasia. Long term follow up studies of all patients with AIN are required to determine if this could be used as a marker of likely disease progression from high grade AIN to invasive disease. There does not seem to be an association between the presence or absence of HPV 16 DNA sequences and mutant p53 proteins in anal squamous neoplasia.

Full text

PDF
508

Images in this article

509Image
on p.509

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bartek J., Iggo R., Gannon J., Lane D. P. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene. 1990 Jun;5(6):893–899. [PubMed] [Google Scholar]
  2. Bennett W. P., Hollstein M. C., He A., Zhu S. M., Resau J. H., Trump B. F., Metcalf R. A., Welsh J. A., Midgley C., Lane D. P. Archival analysis of p53 genetic and protein alterations in Chinese esophageal cancer. Oncogene. 1991 Oct;6(10):1779–1784. [PubMed] [Google Scholar]
  3. Bennett W. P., Hollstein M. C., He A., Zhu S. M., Resau J. H., Trump B. F., Metcalf R. A., Welsh J. A., Midgley C., Lane D. P. Archival analysis of p53 genetic and protein alterations in Chinese esophageal cancer. Oncogene. 1991 Oct;6(10):1779–1784. [PubMed] [Google Scholar]
  4. Bártek J., Bártková J., Vojtesek B., Stasková Z., Lukás J., Rejthar A., Kovarík J., Midgley C. A., Gannon J. V., Lane D. P. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene. 1991 Sep;6(9):1699–1703. [PubMed] [Google Scholar]
  5. Børresen A. L., Helland A., Nesland J., Holm R., Trope C., Kaern J. Papillomaviruses, p53, and cervical cancer. Lancet. 1992 May 30;339(8805):1350–1351. [PubMed] [Google Scholar]
  6. Cattoretti G., Rilke F., Andreola S., D'Amato L., Delia D. P53 expression in breast cancer. Int J Cancer. 1988 Feb 15;41(2):178–183. doi: 10.1002/ijc.2910410204. [DOI] [PubMed] [Google Scholar]
  7. Crook T., Wrede D., Tidy J. A., Mason W. P., Evans D. J., Vousden K. H. Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus-negative tumours. Lancet. 1992 May 2;339(8801):1070–1073. doi: 10.1016/0140-6736(92)90662-m. [DOI] [PubMed] [Google Scholar]
  8. Crook T., Wrede D., Tidy J., Scholefield J., Crawford L., Vousden K. H. Status of c-myc, p53 and retinoblastoma genes in human papillomavirus positive and negative squamous cell carcinomas of the anus. Oncogene. 1991 Jul;6(7):1251–1257. [PubMed] [Google Scholar]
  9. Gusterson B. A., Anbazhagan R., Warren W., Midgely C., Lane D. P., O'Hare M., Stamps A., Carter R., Jayatilake H. Expression of p53 in premalignant and malignant squamous epithelium. Oncogene. 1991 Oct;6(10):1785–1789. [PubMed] [Google Scholar]
  10. Hall P. A., Ray A., Lemoine N. R., Midgley C. A., Krausz T., Lane D. P. p53 immunostaining as a marker of malignant disease in diagnostic cytopathology. Lancet. 1991 Aug 24;338(8765):513–513. doi: 10.1016/0140-6736(91)90586-e. [DOI] [PubMed] [Google Scholar]
  11. Hollstein M., Sidransky D., Vogelstein B., Harris C. C. p53 mutations in human cancers. Science. 1991 Jul 5;253(5015):49–53. doi: 10.1126/science.1905840. [DOI] [PubMed] [Google Scholar]
  12. Kastan M. B., Onyekwere O., Sidransky D., Vogelstein B., Craig R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991 Dec 1;51(23 Pt 1):6304–6311. [PubMed] [Google Scholar]
  13. Midgley C. A., Fisher C. J., Bártek J., Vojtesek B., Lane D., Barnes D. M. Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli. J Cell Sci. 1992 Jan;101(Pt 1):183–189. doi: 10.1242/jcs.101.1.183. [DOI] [PubMed] [Google Scholar]
  14. Nigro J. M., Baker S. J., Preisinger A. C., Jessup J. M., Hostetter R., Cleary K., Bigner S. H., Davidson N., Baylin S., Devilee P. Mutations in the p53 gene occur in diverse human tumour types. Nature. 1989 Dec 7;342(6250):705–708. doi: 10.1038/342705a0. [DOI] [PubMed] [Google Scholar]
  15. Ogden G. R., Kiddie R. A., Lunny D. P., Lane D. P. Assessment of p53 protein expression in normal, benign, and malignant oral mucosa. J Pathol. 1992 Apr;166(4):389–394. doi: 10.1002/path.1711660411. [DOI] [PubMed] [Google Scholar]
  16. Palmer J. G., Scholefield J. H., Coates P. J., Shepherd N. A., Jass J. R., Crawford L. V., Northover J. M. Anal cancer and human papillomaviruses. Dis Colon Rectum. 1989 Dec;32(12):1016–1022. doi: 10.1007/BF02553872. [DOI] [PubMed] [Google Scholar]
  17. Penn I. Cancers of the anogenital region in renal transplant recipients. Analysis of 65 cases. Cancer. 1986 Aug 1;58(3):611–616. doi: 10.1002/1097-0142(19860801)58:3<611::aid-cncr2820580303>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  18. Pinion S. B., Kennedy J. H., Miller R. W., MacLean A. B. Oncogene expression in cervical intraepithelial neoplasia and invasive cancer of cervix. Lancet. 1991 Apr 6;337(8745):819–820. doi: 10.1016/0140-6736(91)92518-7. [DOI] [PubMed] [Google Scholar]
  19. Riou G., Barrois M., Lê M. G., George M., Le Doussal V., Haie C. C-myc proto-oncogene expression and prognosis in early carcinoma of the uterine cervix. Lancet. 1987 Apr 4;1(8536):761–763. doi: 10.1016/s0140-6736(87)92795-4. [DOI] [PubMed] [Google Scholar]
  20. Riou G., Barrois M., Lê M. G., George M., Le Doussal V., Haie C. C-myc proto-oncogene expression and prognosis in early carcinoma of the uterine cervix. Lancet. 1987 Apr 4;1(8536):761–763. doi: 10.1016/s0140-6736(87)92795-4. [DOI] [PubMed] [Google Scholar]
  21. Rivas C. I., Wisniewski D., Strife A., Perez A., Lambek C., Bruno S., Darzynkiewicz Z., Clarkson B. Constitutive expression of p53 protein in enriched normal human marrow blast cell populations. Blood. 1992 Apr 15;79(8):1982–1986. [PubMed] [Google Scholar]
  22. Rodrigues N. R., Rowan A., Smith M. E., Kerr I. B., Bodmer W. F., Gannon J. V., Lane D. P. p53 mutations in colorectal cancer. Proc Natl Acad Sci U S A. 1990 Oct;87(19):7555–7559. doi: 10.1073/pnas.87.19.7555. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Sasano H., Goukon Y., Nishihira T., Nagura H. In situ hybridization and immunohistochemistry of p53 tumor suppressor gene in human esophageal carcinoma. Am J Pathol. 1992 Sep;141(3):545–550. [PMC free article] [PubMed] [Google Scholar]
  24. Scheffner M., Werness B. A., Huibregtse J. M., Levine A. J., Howley P. M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990 Dec 21;63(6):1129–1136. doi: 10.1016/0092-8674(90)90409-8. [DOI] [PubMed] [Google Scholar]
  25. Scholefield J. H., Sonnex C., Talbot I. C., Palmer J. G., Whatrup C., Mindel A., Northover J. M. Anal and cervical intraepithelial neoplasia: possible parallel. Lancet. 1989 Sep 30;2(8666):765–769. doi: 10.1016/s0140-6736(89)90830-1. [DOI] [PubMed] [Google Scholar]
  26. Van der Meer J. T., Van Wijk W., Thompson J., Vandenbroucke J. P., Valkenburg H. A., Michel M. F. Efficacy of antibiotic prophylaxis for prevention of native-valve endocarditis. Lancet. 1992 Jan 18;339(8786):135–139. doi: 10.1016/0140-6736(92)90207-j. [DOI] [PubMed] [Google Scholar]
  27. Vojtesek B., Bártek J., Midgley C. A., Lane D. P. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods. 1992 Jul 6;151(1-2):237–244. doi: 10.1016/0022-1759(92)90122-a. [DOI] [PubMed] [Google Scholar]
  28. Werness B. A., Levine A. J., Howley P. M. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science. 1990 Apr 6;248(4951):76–79. doi: 10.1126/science.2157286. [DOI] [PubMed] [Google Scholar]
  29. Wexner S. D., Milsom J. W., Dailey T. H. The demographics of anal cancers are changing. Identification of a high-risk population. Dis Colon Rectum. 1987 Dec;30(12):942–946. doi: 10.1007/BF02554281. [DOI] [PubMed] [Google Scholar]
  30. Young L. S., Bevan I. S., Johnson M. A., Blomfield P. I., Bromidge T., Maitland N. J., Woodman C. B. The polymerase chain reaction: a new epidemiological tool for investigating cervical human papillomavirus infection. BMJ. 1989 Jan 7;298(6665):14–18. doi: 10.1136/bmj.298.6665.14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Zur Hausen H. Papillomaviruses in human cancers. Mol Carcinog. 1988;1(3):147–150. doi: 10.1002/mc.2940010302. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES